Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 24-week, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Secukinumab in Controlling Spinal Pain in Patients With Axial Spondyloarthritis

Trial Profile

A 24-week, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Secukinumab in Controlling Spinal Pain in Patients With Axial Spondyloarthritis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Nov 2018

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Ankylosing spondylitis; Pain
  • Focus Therapeutic Use
  • Acronyms SKIPPAIN
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 22 Nov 2018 This trial was completed in Finland, according to European Clinical Trials Database.
    • 13 Aug 2018 Planned primary completion date changed from 2 Nov 2018 to 22 Feb 2019.
    • 13 Aug 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top